Syndrome News and Research

RSS

COVID-19 vaccination remains Australia's best option for a return to normal, say researchers

Researchers in Australia and the United States have advised that the recent decision in Australia to prioritize older vulnerable age groups for vaccination against coronavirus disease 2019 (COVID-19) represents the optimal strategy for reducing deaths caused by the disease.

20 Jul 2021

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Researchers in Canada have developed an adenoviral vector-based vaccine against coronavirus disease 2019 (COVID-19) that induced robust immune protection against the ancestral strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice.

20 Jul 2021

Child with Bachmann-Bupp Syndrome successfully treated in just 16 months

Diagnosing a rare medical condition is difficult. Identifying a treatment for it can take years of trial and error. In a serendipitous intersection of research expertise, an ill patient in this case a child and innovative technology, Bachmann-Bupp Syndrome has gone from a list of symptoms to a successful treatment in just 16 months.

20 Jul 2021

Novel method for glucagon delivery to help individuals living with Type 1 diabetes

For children with Type 1 diabetes, the risk of experiencing a severe hypoglycemic episode is especially common -- and for parents, the threat of that happening in the middle of the night is especially frightening.

20 Jul 2021

$40 million multi-year study to examine long-term impacts of COVID-19 and MIS-C

Up to 2,000 children and young adults will be enrolled in a study from Children's National Hospital in collaboration with the National Institute of Allergy and Infectious Diseases that will examine the long-term effects of COVID-19 and multisystem inflammatory syndrome in children (MIS-C) after these patients have recovered from a COVID-19 infection.

20 Jul 2021

CEPI and IVI announce new research program to expand access to COVID-19 vaccines in Africa

The Coalition for Epidemic Preparedness Innovations and the International Vaccine Institute today announced a new programme of clinical research which aims to expand access to COVID-19 vaccines in Africa.

20 Jul 2021

Researchers examine the effectiveness of the Pfizer-BioNTech COVID-19 vaccine in reducing household transmission

A new study has been published on the medRxiv* preprint server, which focuses on the effectiveness of the BNT162b2 vaccine by studying the susceptibility of a vaccinated individual to infection. The researchers have also studied the effect of the vaccine on virus transmission.

20 Jul 2021

Study examines clinical outcomes in vaccinated individuals hospitalized with SARS-CoV-2 Delta variant

A new study has been published on the medRxiv* preprint server that has evaluated the clinical outcomes of the COVID-19 patients hospitalized in AIG hospitals, Hyderabad, India, between April 24, 2021, and May 31, 2021.

20 Jul 2021

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

A new study reports this finding, along with varying antibody prevalence among different groups and regions and between different age groups. In the current paper, available as a preprint on the medRxiv* server, the results of the sixth round of the REACT-2 study are reported.

20 Jul 2021

Study suggests COVID-19 vaccine confidence and hesitancy in the UK driven by trust, not misinformation

An interesting new study reports that vaccine hesitancy in the UK is driven not, as is commonly thought, by the so-called ‘infodemic’ of misinformation that has characterized much public messaging during the COVID-19 pandemic. Instead, the personality of the individual, the ability to trust scientific and government leadership, political affiliations, and openness relative to the process of vaccine development was found to be key in the development of this attitude.

20 Jul 2021

COVID-19 vaccination in New York City reduces hospital admissions and deaths

A new study, released as a preprint on the medRxiv* server, shows how the successful rollout of effective COVID-19 vaccines in this metropolis led to the dramatic reduction in the number of cases with moderate to severe coronavirus disease 2019 (COVID-19) and curbed COVID-19-related mortality.

20 Jul 2021

Graduate student receives NIH grant to study specific molecule’s role in healthy neurodevelopment

Raymundo Hernandez was always drawn to psychology - that is, until he took his first neurobiology class as an undergraduate.

20 Jul 2021

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

The ongoing coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 190 million cases worldwide. Of these, over 4 million have died due to the infection.

20 Jul 2021

How SARS-CoV-2 infects the brain

While there is no official explanation on how SARS-CoV-2 travels to the brain, a new review published in the journal Fluids and Barriers of the CNS concluded that there is insufficient evidence on COVID-induced neurological problems coming from a direct invasion of SARS-CoV-2 into the brain.

20 Jul 2021

Study proves effectiveness of Artemisia annua against SARS-CoV-2 in vitro

A multinational research group has been the first to show the excellent activity of artemisinin-based treatment against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human cell lines – including a specific type of lung cells. Their findings were recently published in the journal Scientific Reports.

19 Jul 2021

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Researchers in the United States have conducted a study suggesting that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit better neutralizing activity against variants of concern following vaccination against coronavirus disease 2019 (COVID-19) than previously uninfected vaccinees.

19 Jul 2021

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Researchers in Finland have conducted a study showing that the neutralizing bodies generated following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – generally persist for at least a year.

19 Jul 2021

Syndrome News and Research

COVID-19 vaccination remains Australia's best option for a return to normal, say researchers

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Child with Bachmann-Bupp Syndrome successfully treated in just 16 months

Novel method for glucagon delivery to help individuals living with Type 1 diabetes

$40 million multi-year study to examine long-term impacts of COVID-19 and MIS-C

CEPI and IVI announce new research program to expand access to COVID-19 vaccines in Africa

Researchers examine the effectiveness of the Pfizer-BioNTech COVID-19 vaccine in reducing household transmission

Study examines clinical outcomes in vaccinated individuals hospitalized with SARS-CoV-2 Delta variant

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

Study suggests COVID-19 vaccine confidence and hesitancy in the UK driven by trust, not misinformation

COVID-19 vaccination in New York City reduces hospital admissions and deaths

Graduate student receives NIH grant to study specific molecule’s role in healthy neurodevelopment

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

How SARS-CoV-2 infects the brain

Study proves effectiveness of Artemisia annua against SARS-CoV-2 in vitro

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Iodine derivative kills SARS-CoV-2 within 90 sec

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

Functional autoantibody in COVID-19 contributes to the 'firestorm' of blood clots and inflammation

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News